A significant percentage of eukaryotic proteins contain posttranslational modifications, including glycosylation, which are required for biological function.
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INTRODUCTION
Therapeutic proteins are the fastest growing source of new therapies in the biopharmaceutical industry (Walsh, 2000) . The resulting demand for more efficient protein expression systems is leading the industry to seek alternatives to existing expression hosts. In contrast to mammalian cell lines, which are the preferred vehicle for the expression of most glycoproteins, yeast-based expression systems offer a variety of advantages including: shorter fermentation times, cheaper operating costs, chemically defined media, no viral contamination, higher protein titers, and much shorter development times from gene to protein. However, the inability to replicate human glycosylation has prevented yeast and other fungal hosts from becoming a suitable expression host for therapeutic glycoprotein production.
The processing of asparagine-linked glycans transferred onto a protein differs significantly between higher and lower eukaryotes. The initial stage, highly conserved throughout eukarya, comprises the assembly of a lipid-linked oligosaccharide, Glc 3 Man 9 GlcNAc 2 , followed by its transfer to the nascent protein and the removal of three glucoses and one mannose to yield Man 8 GlcNAc 2 (Fig. 1A , Kornfeld and Kornfeld, 1985; Burda and Aebi, 1999) . In the second stage, localized in the Golgi, the proteinlinked N-glycans are further modified along pathways that diverge significantly across species. Yeast and other fungi typically produce high mannose type N-glycans by adding up to 100 mannose sugars, whereas the formation of mammalian glycans generally involves the trimming of mannose followed by the addition of N-acetylglucosamine, at Pennsylvania State University on http://glycob.oxfordjournals.org/ Downloaded from 10:02 AM5/25/04 4 galactose, fucose and sialic acid ( Fig. 1 ; Dean, 1999; Gemmill and Trimble, 1999; Kukuruzinska and Lennon, 1998; Moremen et al., 1994) .
The replication of the human N-linked glycosylation machinery in a fungal host requires the cloning, functional expression and proper targeting of several mannosidase and glycosyltransferase enzymes, with each enzyme operating at high efficiency. Previously, we have described the genetic engineering of N-glycosylation in the yeast Pichia pastoris, developing a strain that produces the hybrid N-glycan GlcNAcMan 5 GlcNAc 2 on a secreted reporter protein (Choi et al., 2003, Fig. 3B ). This was accomplished by creating combinatorial genetic libraries of protein fusions of fungal type II membrane leaders and catalytic domains of glycosylation enzymes. After transforming these genetic fusion libraries into a P. pastoris strain containing a UDPGlcNAc transporter and lacking fungal specific α−1,6-mannosyltransferase activity (Och1p), we were able to identify specific combinations of α-1,2-mannosidases (MNS I) and N-acetylglucosaminyltransferases I (GnT I) that efficiently replicated early human Nglycan processing (GlcNAcMan 5 in Fig. 1B and Fig. 2 ).
In humans, the subsequent steps of glycosylation involve the removal of the terminal α-1,3-and α-1,6-linked mannoses from GlcNAcMan 5 GlcNAc 2 by α-mannosidase II (Tulsiani et al., 1982) . This exposes the α-1,6 mannose residue of the trimannose core, which is then extended by N-acetylglucosaminyltransferase II (GnT II, Bendiak and Schachter, 1987, Fig. 1A) . This biosynthetic pathway, leading to complex N-glycans, was recently replicated in P. pastoris .
In the present work, rather than expressing and targeting mannosidase II, we report an alternative strategy to produce a yeast strain capable of assembling complex N- shown to encode the Dol-P-Man:Man 5 GlcNAc 2 -PP-Dol α-1,3-mannosyltransferase, which is responsible for the first Dol-P-Man-dependent mannosyl transfer step converting Man 5 GlcNAc 2 -PP-Dol to Man 6 GlcNAc 2 -PP-Dol in the lumen of the ER (Sharma et al., 2001) . The deletion of ALG3 in S. cerevisiae and P. pastoris results in the transfer of Glc 3 Man 5 GlcNAc 2 to nascent polypeptides, albeit at a somewhat reduced efficiency (Aebi et al., 1996; Davidson et al., 2004) . It was demonstrated previously in some mutant mammalian cell lines that the synthesis of dolichol-linked oligosaccharides is blocked at the Man 5 GlcNAc 2 -PP-Dol stage (resembling the lack of Alg3p activity). Despite the inability of those cells to make the mature Glc 3 Man 9 GlcNAc 2 -PP-Dol, they retained the ability to produce complex-type N-glycans (Kornfeld et al., 1979; Stoll et al., 1982; Lehrman and Zeng, 1989) . We reasoned that a yeast alg3 mutant strain expressing a properly targeted and active α-1,2-mannosidase should be able to generate a Man 3 GlcNAc 2 structure, an artificial glycosylation intermediate that could be further modified to form a complex N-glycan. Previous work by Schachter and coworkers, which demonstrated that Man 3 GlcNAc 2 can serve as an acceptor for Nacetylglucosamine-transfer by GnTI in vitro, led us to attempt the replication of this reaction in vivo in a yeast (Narasimham et al., 1977; Vella et al., 1984 ). Here we demonstrate that blocking the assembly of the yeast core oligosaccharide, combined with the subsequent use of combinatorial genetic libraries to target mammalian glycosylation enzymes to the secretory pathway, enabled us to engineer a P. pastoris strain that 
Results

Deletion of PpALG3 in a strain producing hybrid type N-glycans.
In our previous work, we described the deletion of OCH1 in P. pastoris, resulting in the loss of outer chain initiating α-1,6-mannosyltransferase activity (Fig. 1A and Choi et al., 2003) . Replication of hybrid-type human glycosylation required the proper targeting of several active glycosylation enzymes, which was achieved via the use of extensive combinatorial libraries of fungal ER and Golgi targeting domains fused to catalytic domains from mannosidases and glycosyl transferases (Choi et al., 2003) . (Choi et al., 2003) .
In mammals, GlcNAcMan 5 GlcNAc 2 is modified by the removal of the two terminal mannoses from the 1,6-arm by mannosidase II to produce GlcNAcMan 3 GlcNAc 2 (Fig. 1A) . We reasoned that the elimination of Alg3p activity from a P. pastoris strain producing GlcNAcMan 5 GlcNAc 2 glycans would result in a strain producing the artificial N-glycan intermediate GlcNAcMan 3 GlcNAc 2 , and obviate the need for mannosidase II (Fig. 2) . Previously, we reported the cloning and deletion of PpALG3 in an och1 mutant strain of P. pastoris (Davidson et al, 2004) . From a variety of K3 secreting strains generated in our laboratory we selected strain PBP3, an och1 deletion that contains catalytic domains of mouse MNS I and human GnT I fused to yeast (Choi et al., 2003; Hamilton et al., 2003) .
The PpALG3 gene was deleted in the PBP3 strain background using a PCR generated alg3::G418 R deletion allele to create strain RDP27 (Fig. 2) . MALDI-TOF MS analysis of N-glycans released from K3 demonstrated that the major glycoform was of a mass consistent with GlcNAcMan 3 GlcNAc 2 ( Fig. 3 ) with a few additional N-glycans of higher molecular mass. MALDI-TOF analysis following in vitro β-NAcetylhexosaminidase and α-1,2-mannosidase digest indicate that these glycans contain one terminal β-linked GlcNAc and up to four α-1,2-mannose sugars (data not shown).
The addition of α-1,2-linked mannose in the Golgi has previously been shown to occur in both P. pastoris and S. cerevisiae Dean, 1999; Verostek and Trimble, 1995) . Our data suggest that the alg3 mutant strain produces an "alg3 Man 5 " structure ( Fig. 1B ) that serves as a substrate for MNS I resulting in a synthetic 
Complex N-Glycan Production -Functional Expression of GnT II
In mammalian cells, the GlcNAcMan 3 GlcNAc 2 structure generated by mannosidase II serves as a substrate for GnT II. 10:02 AM5/25/04 9 essential step in the biosynthesis of complex-type N-glycans. While RDP27 generates mostly GlcNAcMan 3 GlcNAc 2 structures, the above mentioned experiments also suggest that endogenous α-1,2-mannosyltransferases are able to convert some GlcNAcMan 3 GlcNAc 2 to GlcNAcMan 4-7 GlcNAc 2 . We postulated that localization of an active GnT II catalytic domain early in the Golgi could preempt this addition of α-1,2-mannoses, leading to GlcNAc 2 Man 3 GlcNAc 2 , which would not be a substrate for subsequent α-1,2-mannose transfer. Utilizing a strategy previously reported (Choi et al., 2003) , several dozen chimeric constructs consisting of cDNA fragments encoding a rat
GnT II catalytic domain were generated by fusion to a library of yeast Golgi targeting sequences and transformed into P. pastoris strain RDP27. MALDI-TOF MS analysis of N-glycans released from secreted K3 identified several strains able to produce N-glycans of a mass consistent with GlcNAc 2 Man 3 GlcNAc 2 (Fig. 3) . One of these strains (PBP6-5) containing a leader sequence from the S. cerevisiae MNN9 gene produced glycans with a nearly uniform GlcNAc 2 Man 3 GlcNAc 2 structure (Fig. 3D ). The identity of the GlcNAc 2 Man 3 GlcNAc 2 structure was confirmed by NMR analysis and digestion with β-N-acetylhexosaminidase (data not shown). Furthermore, the purified K3 protein from strain PBP6-5 was incubated with β-1,4-galactosyltransferase (GalT) in the presence of UDP-galactose. MALDI-TOF MS analysis demonstrates that the GlcNAc 2 Man 3 GlcNAc 2 N-glycans on this protein had received two galactose residues and thus, as expected, can serve as a substrate for subsequent mammalian-type modification (data not shown).
In addition, we previously reported that the deletion of PpALG3 in an och1 mutant background leads to the occurrence of several larger glycans ranging from Hex 6 GlcNAc 2 to Hex 12 GlcNAc 2 , which are recalcitrant to an array of mannosidase digests (Davidson et al., 2004) . The presence of structures larger than Man 5 GlcNAc 2 suggests the action of additional, yet unidentified, transferases capable of transferring sugars to the "alg3 Man 5 "
glycan. Interestingly, the high uniformity of the GlcNAc 2 Man 3 GlcNAc 2 N-glycans observed here suggests that these unknown transferases are now depleted of their substrate, and thus are no longer capable of adding hexoses.
In vivo transfer of galactose in an alg3 mutant strain producing complex N-glycans
We sought to confirm the identity of the GlcNAc 2 Man 3 GlcNAc 2 structure and show that quantitative in vivo galactose transfer is possible on a complex structure produced in an alg3 mutant strain. Previous experiments demonstrated that galactose transfer in P. pastoris required not only the presence of a galactosyl transferase but also the generation of a pool of precursor (UDP-galactose) and the transport of the precursor into the Golgi (Davidson et al, unpub. data) . Recently, an active secreted fusion protein of E. coli UDP-galactose 4-epimerase and bovine α-1,3-galactosyltransferase has been reported (Chen et al., 2000) . We reasoned that if there was sufficient UDP-glucose in the yeast Golgi, an analogous fusion protein might function as a type II membrane protein localized to the Golgi and supply a localized pool of UDP-galactose, eliminating the need for a membrane transporter. Thus, a three-part fusion gene was constructed using engineered restriction sites, which encodes the first 36 amino acids of ScMnn2, the fulllength protein predicted to be a UDP-galactose 4-epimerase from Schizosaccharomyces pombe, and human GalT I lacking the first 43 amino acids. This fusion gene was cloned downstream of the PpGAPDH promoter and introduced into strain PBP6-5.
Transformants were analyzed by MALDI-TOF MS and several resulting strains were 10:02 AM5/25/04 11 obtained in which the majority of N-glycans were of a mass consistent with Gal 2 GlcNAc 2 Man 3 GlcNAc 2 or addition of two galactose residues to the N-glycans produced in PBP6-5. The MALDI-TOF MS spectrum of N-glycans resulting from one of these strains, designated RDP93, is shown (Fig. 3E) . The mass of the N-glycans resulting from strain RDP93 exactly corresponds with that obtained from in vitro addition of galactose to N-glycans purified from strain PBP6-5 (data not shown). Furthermore, in vitro β-galactosidase digest resulted in N-glycans of a mass consistent with GlcNAc 2 Man 3 GlcNAc 2 confirming the identity of the two additional hexose residues as galactose (data not shown).
Performance Comparison of Genetically Reengineered Strains
To determine the impact of these genetic modifications on heterologous protein expression, several shake flask and fermentation experiments were performed. A standardized shake flask protocol was used to determine K3 production levels in wildtype P. pastoris (BK64), och1 mutant (BK3-1), PBP3, RDP27 and PBP6-5 (Fig. 2) . SDS-PAGE analysis of supernatants from these shake flasks revealed similar protein production levels for all five strains (Fig. 4A) . Fermentation experiments were conducted to assess the scale-up characteristics of PBP6-5. The specific productivity of PBP6-5 observed in shake flask experiments (2.2 mg/OD 600 /day) was conserved in the bioreactor (2.2 mg/OD 600 /day). Furthermore, the specific productivities observed in bioreactor experiments between PBP6-5 (2.2 mg/OD 600 /day) and BK64 (2.6 mg/OD 600 /day) were similar. Cueva et al., 1996) . While the unglycosylated fraction is a relatively small portion of the total K3 produced, reduced occupancy in these strains will have to be monitored on several proteins to determine the severity of this effect. MALDI-TOF analysis of the glycans released from K3 produced by PBP6-5 in the bioreactor demonstrates that the glycan structures are essentially identical to that obtained from shake flasks (Fig 4B vs. 3D ). We thus conclude that the heterologous glycosylation enzymes remain functional and stable when the strain is cultivated under typical industrial fermentation conditions. In previous experiments we observed that expression of human GalT I alone was insufficient to extend complex GlcNAc 2 Man 3 GlcNAc 2 N-glycans to Gal 2 GlcNAc 2 Man 3 GlcNAc 2 because of the apparent lack of a pool of UDP-galactose precursor in the P. pastoris Golgi (Davidson et al, unpub. data) . However, engineered expression of a UDP-galactose 4-epimerase from S. pombe, which converts UDP-glucose to UDP-galactose, successfully generated a pool of UDP-galactose precursor. Combined with expression of a UDP-galactose transporter, to move the UDP-galactose into the Golgi, and the GalT, this enabled us to achieve transfer of galactose onto complex Nglycans in P. pastoris. Here, instead of independent expression of the three necessary As with previous steps, addition of galactose can be engineered to be highly efficient, yielding a strain that produces almost homogenous N-glycans and continuing a theme that has been a hallmark of the glyco-engineered yeast system. The remarkable efficiency of this method in generating and extending complex N-glycans is an important finding for several reasons. Most importantly, this set of experiments demonstrates that an artificial N-glycosylation pathway can be generated, which not only allows for the production of glycans via new pathways but to striking homogeneity. Secondly, our results demonstrate that the alg3 deletion offers an efficient alternative to functionally expressing, properly targeting and maximizing mannosidase II activity. Moreover, the powerful combination of mutation and expression of heterologous enzymes afforded by fungal systems allows one to envision the attempt to assemble virtually any sugar structure in vivo for which a set of enzymes can be collected.
A significant unknown at the outset of this project was in the substrate specificity of the GnT I enzyme expressed in yeast. The endogenous substrate for GnT I in all known higher eukaryotes is Man 5 GlcNAc 2 (Fig. 1A) to which GnT I adds a single GlcNAc in β-1,2 linkage on the 1,3 arm. However, in the scenario described here, the (Fig. 1B) . Analysis of several mammalian cell lines blocked in core assembly reveals that GnT I must act on a Man 3 GlcNAc 2 structure to allow the generation of at least some complex N-glycans in these mutant cell lines (Kornfeld et al., 1979; Stoll et al., 1982; Lehrman and Zeng, 1989) . Based on in vitro studies, some GnT I enzymes are better equipped to handle this assignment than others (Vella et al., 1984; Zhang et al., 2003; Altmann et al., 1993; Strasser et al., 1999 Given the importance of N-glycosylation in such essential cellular functions as cell wall formation, cell division, cell-cycle progression, protein folding, and even glycosylation itself, the effect of an extensively re-engineered N-glycosylation pathway on growth has been an open question. However, the results presented here reveal that drastic changes can be made to the core glycosylation machinery as well as subsequent processing steps of a P. pastoris strain while maintaining viability. Previously, mutations in core glycosylation generated in S. cerevisiae resulted in a reduction in occupancy referred to as under-glycosylation (Aebi, Cueva et al., 1996; Cipollo and Trimble, 2000; Munoz et al., 1994; Basco et al., 1993; Huffaker and Robbins, 1983; MALDI matrices were from Aldrich (Milwaukee, WI).
Construction of an alg3 deletion strain of P. pastoris.
The detailed descriptions of P. pastoris strains BK64 and PBP3 were published previously (Choi et al., 2003; Hamilton et al., 2003) . The alg3:: G418 R allele used for deletion of the PpALG3 gene in strain PBP3 was generated by the PCR overlap method (Davidson et al., 2000) . Primers RCD142 (5'-CCACATCATCCGTGCTACATATAG-10:02 AM5/25/04 18 3') paired with RCD144 (5'-ACGAGGCAAGCTAAACAGATCTCGAAGTATCGAGGGTTATCCAG-3'), RCD145
(5'-CCATCCAGTGTCGAAAACGAGCCAATGGTTCATGTCTATAAATC-3') paired with RCD147 (5'-AGCCTCAGCGCCAACAAGCGATGG-3'), and RCD143 (5'-CTGGATAACCCTCGATACTTCGAGATCTGTTTAGCTTGCCTCGT-3') paired with RCD146 (5'-GATTTATAGACATGAACCATTGGCTCGTTTTCGACACTGGATGG-3') were used to amplify the 5' and 3' flanking regions of the ALG3 gene and the G418 resistance marker (G418 R ), respectively. Then, primers RCD142 and RCD147 were used in a second reaction with all three first round templates to generate an overlap product that contained all three fragments as a single linear alg3::G418 R allele. This PCR product was then directly employed for transformation with selection on medium containing 200 µg/ml of G418. Primers MG1 (5'-TCTGGTAGATCCATTAGTTGCTGC-3') and PTEF (5'-AGCTGCGCACGTCAAGACTGTCAAGGA-3') and MG6 (5'-ATTCTCCATATGCTCAACCTAACG-3') and KAN10 were used to confirm proper integration of the alg3::G418 R mutant allele at the 5' and 3' junctions, respectively, and primers RCD178 (5'-TTTATGGTTAGCTGATTCCATTGTTAT-3') and RCD179 (5'-ATCAAAACTAGAACAGGTGCCAAGGCT-3') were used to confirm the absence of the wild-type ALG3 allele. PBP3 strain with confirmed deletion of PpALG3 was named RDP27. encoding rat GnT II, pTC53, was linearized with the restriction enzyme EcoRI, and transformed into strain RDP27, and transformants were selected on YPD medium containing 100 µg/ml Nourseothricin (Werner BioAgents).
Construction of a GnT
Construction and expression of a UDP-galactose 4-epimerase/galactosyl transferase fusion construct
A gene encoding UDP-galactose 4-epimerase activity was previously amplified from S. pombe genomic DNA and cloned to generate plasmid pRCD406 (unpub. data).
The SpGALE gene was subsequently amplified using primers RCD326 (5'- Reporter protein purification and release of N-linked glycans.
The K3 domain, under the control of the P. pastoris alcohol oxidase 1 (AOX1)
promoter, was used as a model protein and was purified using the 6xHistidine tag as reported previously (Choi et al., 2003) . The glycans were released and separated from the glycoproteins by a modification of a previously reported method (Papac et al., 1998) .
After the proteins were reduced and carboxymethylated, and the membranes blocked, the wells were washed three times with water. The protein was deglycosylated by the addition of 30 µl of 10 mM NH 4 HCO 3 pH 8.3 containing one milliunit of N-glycanase (Glyko). After 16 hr at 37 o C, the solution containing the glycans was removed by centrifugation and evaporated to dryness.
Analysis of K3 production in shake-flasks and bioreactor
The total protein in the supernatant (after 10 min of centrifugation at 3000g) of flask and fermentation samples were analyzed using the Bio-Rad Protein Assay (Cat No 500-0001) using BSA as a standard. Protein purity was assayed by quantitatively comparing the grey scale intensity of the bands on a SDS-PAGE (4-20% Tris-HCl, BioRad Cat No 161-1123, Stained with Coomassie blue according to Laemmli, 1970 ) by using a freeware image analysis package (ImageJ 1.29x Wayne Rasband, National
Institutes of Health, USA, Java 1.3.1_03). Images of the SDS-PAGE gels were captured using a digital camera and stored in a jpeg format. and assessing the amount of purified protein using both the Bio-Rad assay and
Absorbance at 420nm after ensuring purity on an SDS-PAGE. For the shake-flask cultivations, a single colony was picked from a YPD plate (<2 weeks old) containing the strain of interest and inoculated into 10 ml of BMGY medium in a 50ml "Falcon" centrifuge tube. The culture was grown to saturation at 24ºC (approx. 48 hours). The seed culture was transferred into a 500 ml baffled volumetric flask containing 150 ml of BMGY medium and grown to OD 600 of 7±0.5 at 24º C (approx. 24 hours). The growth rate of the cells was determined as the slope of a plot of the natural logarithm of OD 600 against time. The cells were harvested from the growth medium (BMGY) by centrifugation at 3000g for 10 minutes, washed with BMMY and suspended in 15 ml of BMMY in a 250 ml baffled volumetric flask. After 24 hours, the expression medium flask is harvested by centrifugation (3000g for 10 minutes) and the supernatant analyzed for K3 production.
For bioreactor cultivations a 500 ml baffled volumetric flask with 150 ml of BMGY media was inoculated with 1 ml of seed culture (see flask cultivations). The inoculum was grown to an OD 600 of 4-6 at 24º C (approx 18 hours). The cells from the inoculum culture were then centrifuged and resuspended into 50 ml of fermentation 5.00ml).
Fermentations were conducted in 3 liter dished bottom (1.5 liter initial charge volume) Applikon bioreactors. The fermenters were run in a fed-batch mode at a temperature of 24º C, and the pH was controlled at 4.5 ±0.1 using 30% ammonium hydroxide. The dissolved oxygen (DO) was maintained above 40% relative to saturation with air at 1 atm by adjusting agitation rate (450-900 rpm) and pure oxygen supply. The air flow rate was maintained at 1 vvm. When the initial glycerol (40g/l) in the batch phase is depleted, which is indicated by an increase of DO, a 50% glycerol solution containing 12 ml/l of PTM 1 salts was fed at a feed rate of 12 ml/l/h until the desired biomass concentration was reached. After a starvation phase of 30 minutes, the methanol feed (100% Methanol with 12 ml/l PTM 1 ) is initiated. The methanol feed rate is used to control the methanol concentration in the fermenter between 0.2 and 0.5%. The methanol concentration is measured online using a TGS gas sensor (TGS822 from Figaro Engineering Inc.) located in the offgass from the fermenter. The fermenters were sampled every eight hours and analyzed for biomass (OD 600 , wet cell weight and cell counts), residual carbon source level (glycerol and methanol by HPLC using Aminex 87H) and extracellular protein content (by SDS-PAGE, and Bio-Rad protein assay).
MALDI/TOF mass spectrometry
Molecular weights of the glycans were determined using a Voyager DE PRO 24 MALDI/TOF mass spectrometer (Applied Biosciences) as described previously (Choi et al., 2003) . Spectra were generated with the instrument in the positive ion mode.
In vitro enzymatic assays
For in vitro galactose transfer, 200 µg of the purified K3 produced in the strain PBP6-5 was incubated with 4 mM UDP-Galactose and 20 to 100 mU of β-1,4-galactosyltransferase (Bovine milk, Calbiochem) in 50 mM NH 4 HCO 3 , 1 mM MnCl 2 , pH 7.5 at 37°C for 20 hr. The glycans were then released and analyzed by MALDI/TOF MS.
The negative control without the enzyme showed no galactose transfer under same conditions.
β-galactosidase digest was carried out in 50 mM ammonium acetate pH5.0 at The engineering of P. pastoris strains resulting in a mutant strain capable of producing complex human N-glycans was accomplished through deletion of PpOCH1 and expression of Mns I and GnT I as described previously (Choi et al., 2003) , followed by deletion of PpALG3 and expression of GnT II. Mns, α-1,2-mannosidase I; GnT I, β-1,2-N-acetylglucosaminyltransferase I; GnT II, β-1,2-N-acetylglucosaminyltransferase II. 
